These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

264 related items for PubMed ID: 211931

  • 21. The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study.
    Engel AG, Tsujihata M, Lindstrom JM, Lennon VA.
    Ann N Y Acad Sci; 1976; 274():60-79. PubMed ID: 1066997
    [Abstract] [Full Text] [Related]

  • 22. Experimental autoimmune myasthenia gravis: the rabbit as an animal model.
    Eldefrawi ME.
    Fed Proc; 1978 Dec; 37(14):2823-7. PubMed ID: 720635
    [Abstract] [Full Text] [Related]

  • 23. A new myasthenic syndrome with end-plate acetylcholinesterase deficiency, small nerve terminals, and reduced acetylcholine release.
    Engel AG, Lambert EH, Gomez MR.
    Ann Neurol; 1977 Apr; 1(4):315-30. PubMed ID: 214017
    [Abstract] [Full Text] [Related]

  • 24. Inhibition of mobilization of acetylcholine: the weak link in neuromuscular transmission during partial neuromuscular block with d-tubocurarine.
    Foldes FF, Chaudhry IA, Kinjo M, Nagashima H.
    Anesthesiology; 1989 Aug; 71(2):218-23. PubMed ID: 2547326
    [Abstract] [Full Text] [Related]

  • 25. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
    Meinl E, Klinkert WE, Wekerle H.
    Am J Pathol; 1991 Nov; 139(5):995-1008. PubMed ID: 1951638
    [Abstract] [Full Text] [Related]

  • 26. The kinetics of transmitter release in myasthenia gravis. I. An electrophysiological analysis of the storage of transmitter.
    Bergmans J, Rosselle N, Verheyen G, Schellens L.
    Electromyogr Clin Neurophysiol; 1972 Nov; 12(5):443-88. PubMed ID: 4350884
    [No Abstract] [Full Text] [Related]

  • 27. [A transferable "myasthenogenic" factor in the serum of patients with myasthenia gravis (author's transl)].
    Toyka KV, Drachman DB, Pestronk A, Fischbeck H, Kao I.
    J Neurol; 1976 Jun 14; 212(3):271-80. PubMed ID: 58978
    [Abstract] [Full Text] [Related]

  • 28. alpha-Neurexins are required for efficient transmitter release and synaptic homeostasis at the mouse neuromuscular junction.
    Sons MS, Busche N, Strenzke N, Moser T, Ernsberger U, Mooren FC, Zhang W, Ahmad M, Steffens H, Schomburg ED, Plomp JJ, Missler M.
    Neuroscience; 2006 Jun 14; 138(2):433-46. PubMed ID: 16406382
    [Abstract] [Full Text] [Related]

  • 29. Passive transfer of the Lambert-Eaton myasthenic syndrome: neuromuscular transmission in mice injected with plasma.
    Kim YI.
    Muscle Nerve; 1985 Feb 14; 8(2):162-72. PubMed ID: 2997605
    [Abstract] [Full Text] [Related]

  • 30. [Effects of aureofuscin on muscle cell membrane and quantal release of acetylcholine (ACh) from the motor nerve terminals].
    Shih YL, Xu YF, Wang WP.
    Sheng Li Xue Bao; 1991 Jun 14; 43(3):286-90. PubMed ID: 1664976
    [Abstract] [Full Text] [Related]

  • 31. Acetylcholine storage, release and leakage at the neuromuscular junction of mature adult and aged rats.
    Smith DO.
    J Physiol; 1984 Feb 14; 347():161-76. PubMed ID: 6323695
    [Abstract] [Full Text] [Related]

  • 32. Effects of epinephrine, ouabain, and insulin in experimental autoimmune myasthenia gravis.
    Takamori M, Mori M, Ide Y, Kasai M.
    Neurology; 1980 Feb 14; 30(2):167-71. PubMed ID: 6243761
    [Abstract] [Full Text] [Related]

  • 33. Neonatal experimental autoimmune myasthenia gravis.
    Sanders DB, Cobb EE, Winfield JB.
    Muscle Nerve; 1978 Feb 14; 1(2):146-50. PubMed ID: 571528
    [Abstract] [Full Text] [Related]

  • 34. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN, Reddel SW, Gervásio OL, Phillips WD.
    Ann Neurol; 2008 Jun 14; 63(6):782-9. PubMed ID: 18384168
    [Abstract] [Full Text] [Related]

  • 35. Experimental myasthenia: lack of correlation between the autoantibody titer and the reduction of acetylcholine-controlled ionic channels measured at functioning endplates.
    Hohlfeld R, Sterz R, Kalies I, Wekerle H, Peper K.
    Muscle Nerve; 1983 Feb 14; 6(2):160-3. PubMed ID: 6304508
    [No Abstract] [Full Text] [Related]

  • 36. End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis.
    Ruff RL, Lennon VA.
    Ann Neurol; 1998 Mar 14; 43(3):370-9. PubMed ID: 9506554
    [Abstract] [Full Text] [Related]

  • 37. Reduction of miniature end-plate potential amplitude in extraocular and limb muscles in an animal model of myasthenia gravis.
    Zahm DS, Kim YI, Liu HH, Johns TR.
    Exp Neurol; 1983 Apr 14; 80(1):258-62. PubMed ID: 6832272
    [Abstract] [Full Text] [Related]

  • 38. X-radiation actions on the neuromuscular transmission.
    Portela A, de Xamar Oro JR, Stewart PA, Gimeno AL, Guardado I, Brennan M, Llobera OH, Pérez JC.
    Acta Physiol Lat Am; 1977 Apr 14; 27(4):157-76. PubMed ID: 214995
    [Abstract] [Full Text] [Related]

  • 39. Congenital myasthenia: end-plate acetylcholine receptors and electrophysiology in five cases.
    Vincent A, Cull-Candy SG, Newsom-Davis J, Trautmann A, Molenaar PC, Polak RL.
    Muscle Nerve; 1981 Apr 14; 4(4):306-18. PubMed ID: 7254233
    [Abstract] [Full Text] [Related]

  • 40. Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice.
    Toyka KV, Drachman DB, Griffin DE, Pestronk A, Winkelstein JA, Fishbeck KH, Kao I.
    N Engl J Med; 1977 Jan 20; 296(3):125-31. PubMed ID: 831074
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.